Jiangsu vcare pharmaceutical technology co., LTD
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING8
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Jiangsu vcare pharmaceutical technology co., LTD on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| VC004 Capsules NCT06658353 |
P3 | Recruiting | Locally Advanced Solid Tumor | 54 | 2026-12-30 |
| Vicagrel NCT06577519 |
P3 | Recruiting | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 1000 | 2026-12-30 |
| VC005 group NCT07598383 |
P2 | Recruiting | Atopic Dermatitis | 120 | 2027-02-22 |
| VC005 tablets NCT07828639 |
P1/2 | Not yet recruiting | Non-Segmental Vitiligo | 10 | 2027-05-30 |
| VC005 tablets NCT07172347 |
P2 | Recruiting | Non-segmental Vitiligo | 120 | 2027-08-30 |
| VC005 tablets NCT07172360 |
P3 | Recruiting | Active Ankylosing Spondylitis | 420 | 2027-08-30 |
| VC005 low dose group NCT06723080 |
P3 | Recruiting | Moderate to Severe Atopic Dermatitis | 480 | 2027-08-30 |
| VC005 NCT07592585 |
P3 | Recruiting | Atopic Dermatitis | 360 | 2028-05-30 |
| Drug: VC005 tablets NCT07749716 |
P2 | Recruiting | Alopecia Areata | 120 | 2028-12-30 |